DDInter1609 DDInter782
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Rivaroxaban {u} (Compound) resembles {v} (Compound) Linezolid
Rivaroxaban {u} (Compound) binds {v} (Gene) ABCB1
Rivaroxaban {u} (Compound) upregulates {v} (Gene) CDK6
Rivaroxaban {u} (Compound) downregulates {v} (Gene) GJA1
Rivaroxaban {u} (Compound) causes {v} (Side Effect) Pruritus
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Rivaroxaban {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Rivaroxaban (Compound) resembles Linezolid (Compound)
Rivaroxaban (Compound) binds ABCB1 (Gene)
Rivaroxaban (Compound) upregulates CDK6 (Gene)
Rivaroxaban (Compound) downregulates GJA1 (Gene)
Rivaroxaban (Compound) causes Pruritus (Side Effect)
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Rivaroxaban may lead to a major life threatening interaction when taken with Regorafenib